Skip to main content
OpenTrials
Completed

NCT Number: NCT00361036

Comparison Study in the Treatment of Uterine Fibroids Uterine Fibroid Embolization Using BeadBlock™ Embolic Agent

A double arm (non-inferiority) 44 patient study to assess the performance of BeadBlock™ in the treatment of uterine fibroids by embolization with respect to clinical & imaging outcome with comparison of primary safety endpoints to Embosphere.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Leiomyoma Female Urogenital Diseases Female Urogenital Diseases and Pregnancy Complications Genital Diseases Genital Diseases, Female Genital Neoplasms, Female Leiomyomatosis Neoplasms Neoplasms by Histologic Type Neoplasms by Site Neoplasms, Connective and Soft Tissue Neoplasms, Muscle Tissue Urogenital Diseases Urogenital Neoplasms Uterine Diseases Uterine Neoplasms

Age range

30 year–50 year

Sex eligibility

Female

Study type

Interventional

Phase

Phase 1

Primary location

Albany Medical Center, Albany, New York, United States

Loading trial locations.

About this study

The purpose of the study is to conduct a comparison between BeadBlock™ and Embosphere in uterine fibroid embolization. Baseline and follow-up MR Imaging data will be made with respect to changes in fibroid and uterus perfusion and fibroid and uterine volume. This is a 12 months study (12 month follow up for all enrollees). The primary end-point will be the degree of fibroid devascularization as seen at contrast-enhanced MRI performed 3 months (+/- 15 days) after UAE procedure. In addition we will assess symptom reduction in patients that have undergone uterine fibroid embolization with Bead Block™ and Embosphere®.

Primary Objective 1. To assess the change in fibroid devascularization as seen at contrast-enhanced MRI performed after UAE and at three (3) months (+/- 15 days) following the UAE, and compare the changes between BeadBlock™ and Embosphere.

Secondary Objective

  • To assess the change in fibroid devascularization as seen at contrast-enhanced MRI performed several days after UAE and 6 months (+/- 15 days) following the UAE, and compare the changes between BeadBlock™ and Embosphere.

Tertiary Objective

  • To assess the change in uterine volume as seen at contrast-enhanced MRI performed several days after UAE, 3 months (+/- 15 days) and 6 months (+/- 15 days) following the UAE, and compare the changes between BeadBlock™ and Embosphere.
  • To assess the change from baseline in symptom severity (UFS-QOL)at 3, 6 and 12 months (+/- 15 days) follow-up, as measured by the subscale of the UFS questionnaire, and compare the changes between BeadBlock™ and Embosphere.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patient chooses to participate and has signed informed consent
  • Age between 30 and 50 years old
  • Symptoms caused by uterine fibroids, such as heavy bleeding (menorrhagia) and/or bulk-related complaints such as urinary frequency, constipation or pelvic pain.
  • Patient has fibroids confirmed by MRI
  • Patient has normal kidney function.
  • Patient is willing and able to undergo follow-up imaging at 3 and 6 months post UFE.

Exclusion criteria

  • Patients who are pregnant or plan to become pregnant within the study period, or desire future fertility.
  • Patients with a history of gynecologic malignancy
  • Patients with known endometrial hyperplasia
  • Patients with adenomyosis
  • Patients with pelvic inflammatory disease
  • Patients with Uteri < 250 ml (cm) calculated volume or > 24 weeks
  • Patients with pedunculated subserosal fibroids with a narrow attachment (<50% diameter of the fibroid) to the uterus.
  • Patients with pelvic pain as dominant syndrome
  • Known allergy to contrast media that cannot be adequately pre-medicated.
  • Patients not suitable for arterial access.
  • Previous uterine artery embolization attempts.
  • History of pelvic irradiation.
  • Patients on GnRH Therapy within 3-6 months prior to the study enrollment.

Treatment and study plan

Uterine fibroid embolization BeadBlock™

Device

Intervention with BeadBlock Microspehere

Uterine fibroid embolization Embosphere®

Device

Embosphere - control arm

Primary outcomes

  1. Change in fibroid devascularization as seen at contrast enhanced MRI performed several days after UAE and 3 months following the UAE between BeadBlock™ and Embosphere

    Time frame: 12 months

Secondary outcomes

  1. Mean difference of change in fibroid devascularization CEMRI performed several days after UAE and 6 months following the UAE between BeadBlock™ and Embosphere.

    Time frame: 12 months

  2. assess the change from baseline in symptom severity (UFS-QOL)at 3, 6 and 12 months (+/- 15 days) follow-up

    Time frame: 12 months

Sponsors and collaborators

Lead sponsor

Worthington-Kirsch, Robert L., M.D.

Indiv

Collaborators

  • Biocompatibles UK Ltd
  • Terumo Medical Corporation

Registry information

Official study title

Feasibility Evaluation of the Embolic Agent BeadBlock™ in the Treatment of Uterine Fibroids With Uterine Artery Embolization With Comparison of Study Endpoints to Embosphere®

Important dates

Study start
2006
Primary completion
2010
Study completion
2010
First posted
Aug 7, 2006
Registry last updated
Apr 18, 2011

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.